• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections.

作者信息

Hoogkamp-Korstanje J A

机构信息

Dept. of Med. Microbiol., St. Radboud Hospital, University of Nijmegen, The Netherlands.

出版信息

Infection. 1995 Sep-Oct;23(5):278-82. doi: 10.1007/BF01716286.

DOI:10.1007/BF01716286
PMID:8557385
Abstract

The efficacy of ciprofloxacin plus metronidazole was compared with that of cefotaxime plus gentamicin plus metronidazole in 79 patients with proven intra-abdominal infections. Patients were classified with the Peritonitis Index Altona-II (PIA-II) score for severity of disease, underlying conditions, prognosis and type of infection. Local peritonitis was diagnosed in 21 patients, generalized peritonitis in 25, intra-abdominal abscesses in 33; 35 patients had polymicrobial infections. Cure and improvement rates were: ciprofloxacin 77%, cefotaxime combination 56% (p < 0.02). Failures were significantly associated with a low initial PIA-II score, the presence of generalized peritonitis or abscesses, persistence of pathogens and superinfection. Superinfection was observed in 49% of the cases under cefotaxime and in 30% under ciprofloxacin. Concentrations of ciprofloxacin in pus ranged 2.0-5.2 mg/l with simultaneous serum concentrations of 1.2-3.1 mg/l.

摘要

相似文献

1
Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections.
Infection. 1995 Sep-Oct;23(5):278-82. doi: 10.1007/BF01716286.
2
Piperacillin/Tazobactam versus cefotaxime plus metronidazole for treatment of children with intra-abdominal infections requiring surgery.哌拉西林/他唑巴坦与头孢噻肟加甲硝唑治疗需手术的儿童腹腔内感染
Eur J Clin Microbiol Infect Dis. 2001 Sep;20(9):643-6. doi: 10.1007/s100960100581.
3
Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections.环丙沙星在治疗住院腹腔内感染患者中的应用。
Clin Ther. 2004 Oct;26(10):1564-77. doi: 10.1016/j.clinthera.2004.10.013.
4
Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.环丙沙星联合甲硝唑与哌拉西林-他唑巴坦治疗复杂性腹腔内感染的药物经济学
Surg Infect (Larchmt). 2008 Jun;9(3):325-33. doi: 10.1089/sur.2007.010.
5
Cefotaxime and metronidazole in severe intra-abdominal infection.
Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):183-8. doi: 10.1016/0732-8893(95)00104-i.
6
The efficacy of pefloxacin in comparison to gentamicin in the treatment of experimentally induced peritonitis in rats.培氟沙星与庆大霉素治疗大鼠实验性腹膜炎的疗效比较。
J Antimicrob Chemother. 1986 Apr;17 Suppl B:59-63. doi: 10.1093/jac/17.suppl_b.59.
7
Prospective, randomized comparison of metronidazole and clindamycin, each with gentamicin, for the treatment of serious intra-abdominal infection.
Surgery. 1983 Jan;93(1 Pt 2):221-9.
8
Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.序贯静脉注射/口服环丙沙星加甲硝唑与静脉注射头孢曲松加甲硝唑治疗复杂性腹腔内感染的比较。
Surg Infect (Larchmt). 2006 Aug;7(4):341-54. doi: 10.1089/sur.2006.7.341.
9
Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S439-43. doi: 10.1093/clinids/4.supplement_2.s439.
10
Clinical evaluation of cefotaxime versus gentamicin plus clindamycin in the treatment of polymicrobial peritonitis.头孢噻肟与庆大霉素加克林霉素治疗混合性腹膜炎的临床评估
Clin Ther. 1982;5 Suppl A:1-9.

引用本文的文献

1
Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults.成人胃肠道源性继发性腹膜炎的抗生素治疗方案
Cochrane Database Syst Rev. 2005 Apr 18;2005(2):CD004539. doi: 10.1002/14651858.CD004539.pub2.
2
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.新型喹诺酮类药物在腹腔内感染治疗中的应用:聚焦于克林沙星
Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522.
3
Prognostic scores and design of clinical studies.

本文引用的文献

1
Intraabdominal infections.
Clin Infect Dis. 1993 Dec;17(6):961-5. doi: 10.1093/clinids/17.6.961.
2
Peritoneal fluid concentrations of gentamicin in patients with spontaneous bacterial peritonitis.自发性细菌性腹膜炎患者腹腔液中庆大霉素的浓度
Antimicrob Agents Chemother. 1981 Feb;19(2):312-5. doi: 10.1128/AAC.19.2.312.
3
Clinical comparison of cefotaxime with gentamicin plus clindamycin in the treatment of peritonitis and other soft-tissue infections.
Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S439-43. doi: 10.1093/clinids/4.supplement_2.s439.
4
Infection. 1998 Sep-Oct;26(5):342-4. doi: 10.1007/BF02962268.
4
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.环丙沙星。对其药理学、治疗效果及耐受性的最新综述。
Drugs. 1996 Jun;51(6):1019-74. doi: 10.2165/00003495-199651060-00010.
Reliability of criteria for predicting persistent or recurrent sepsis.预测持续性或复发性脓毒症标准的可靠性
Arch Surg. 1985 Jan;120(1):17-20. doi: 10.1001/archsurg.1985.01390250011002.
5
A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra-abdominal infections. Report from a Swedish Study Group.
J Antimicrob Chemother. 1990 Oct;26 Suppl B:173-80. doi: 10.1093/jac/26.suppl_b.173.
6
Proposed definitions for diagnosis, severity scoring, stratification, and outcome for trials on intraabdominal infection. Joint Working Party of SIS North America and Europe.腹腔内感染试验的诊断、严重程度评分、分层及预后的拟议定义。北美和欧洲外科感染学会联合工作组
World J Surg. 1990 Mar-Apr;14(2):148-58. doi: 10.1007/BF01664867.
7
Treatment of intra-abdominal infections with quinolones.喹诺酮类药物治疗腹腔内感染
Eur J Clin Microbiol Infect Dis. 1991 Apr;10(4):330-3. doi: 10.1007/BF01967007.
8
Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration.用于治疗腹腔内感染的新型抗感染药物评估。美国传染病学会和美国食品药品监督管理局。
Clin Infect Dis. 1992 Nov;15 Suppl 1:S33-42. doi: 10.1093/clind/15.supplement_1.s33.